NEW YORK, December 30, 2025, 13:47 ET — Regular session
- Arrowhead Pharmaceuticals shares are down sharply in midday trade, outpacing broader biotech declines.
- Focus is shifting to early-January obesity program updates and a J.P. Morgan Healthcare Conference appearance.
- Investors remain keyed on the rollout of REDEMPLO after the company’s first FDA approval.
Arrowhead Pharmaceuticals Inc NASDAQ:ARWR shares were down 3.6% at $67.09 at 1:47 p.m. ET on Tuesday, after trading between $65.94 and $69.95.
The stock’s drop came as biotech weakened but the wider market held steady, a setup that can amplify moves in higher-volatility drug developers. The SPDR S&P Biotech ETF (XBI) fell 1.3% and the iShares Nasdaq Biotechnology ETF (IBB) dropped 1.1%, while the S&P 500 tracker SPY was flat and the Nasdaq-100 proxy QQQ edged higher.
The timing matters because Arrowhead is heading into an early-January news window where it expects to show interim obesity-program data and outline priorities for 2026, which traders often treat as a reset point for biotech positioning.
Arrowhead said it will host a key opinion leader webinar on Jan. 6 to discuss interim clinical data for ARO-INHBE and ARO-ALK7, and is scheduled to give a corporate presentation at the J.P. Morgan 2026 Healthcare Conference on Jan. 12.
RNA-focused peers were also lower on the day, though by less than Arrowhead. Alnylam Pharmaceuticals slipped 0.6% and Ionis Pharmaceuticals fell 1.2%.
Arrowhead’s trading has been volatile since the U.S. FDA approved its first commercial product, REDEMPLO, for familial chylomicronemia syndrome (FCS), a rare inherited disorder linked to very high triglycerides and pancreatitis. “We think Arrowhead’s drug will capture a larger market share,” B. Riley Securities analyst Madison El-Saadi said, citing its profile versus Ionis’ monthly injectable Tryngolza; Reuters also reported REDEMPLO is dosed quarterly and carries an annual wholesale cost of about $60,000. Reuters
REDEMPLO uses RNA interference (RNAi), a gene-silencing approach that reduces production of a specific protein linked to disease. Investors watch RNAi drugmakers closely because a single data update can change expectations for a whole pipeline.
Beyond FCS, Arrowhead is studying plozasiran in Phase 3 trials for severe hypertriglyceridemia, a late-stage study design typically used to support regulatory approval.
With no fresh headline catalyst on Tuesday, price action looked more like positioning than a verdict on fundamentals. That can cut both ways: sector pullbacks often reverse quickly, but they can also snowball when liquidity thins.
What investors will want next is simple and measurable: early signs of REDEMPLO uptake, clarity on reimbursement, and whether management signals confidence in expanding the franchise into broader triglyceride conditions.
The January obesity update is likely to draw extra scrutiny because weight-loss and metabolic drugs remain one of the most crowded — and valuation-sensitive — corners of biotech. Interim data that shows durable effects and a clean safety profile tends to carry outsized influence.
